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Conclusions: SW-VMAT plans aiming at sparing swallowing 
structures are feasible, with the potential to reduce NTCP 
swallowing dysfunction with respect to conventional ST-
VMAT.  
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Purpose/Objective: We present a Fluka Monte Carlo (MC) 
simulation study for proton treatments based on Varian 
Eclipse proton plans for left breast cancers including the 
internal mammary chain. Doses calculated in TPSs are usually 
accurate within the primary field, but less accurate outside. 
With the MC treatment verification we can not only find 
possible inaccuracies in the delivered dose to the regions of 
main interest (PTV and OAR like heart and left lung) mainly 
due to body inhomogeneities close to the PTV (i.e., ribs and 
lung), but also find the accurate dose deposited in other 
healthy tissues not included in the TPS optimisation (contra 
lateral lung, contra lateral breast). Doses deposited by other 
particles not generated in the TPS, but usually created during 
a real treatment, such as neutrons and light ions, are also 
accounded for in the MC. All of this allows us to more 
accurately determine toxicity to healthy tissues and risk of 
secondary malignancies. 
Materials and Methods: Before starting any comparison 
between the MC and the TPS, the virtual CAP GENERAL 
machine used in the proton Eclipse TPS had to be accurately 
characterised. In this context studies were performed using 
virtual water phantoms to determine the beam 
characteristics (energy, energy spread, spatial spread) and so 
to prove the equivalence of Eclipse plans in Fluka.  
Eighteen different patient plans for breast treatments were 
then performed using Eclipse and the information about the 
used beams included in the TPS RTPLAN files were extracted 
and converted to plans in Fluka. This allowed us to perform 
dose comparisons between plans and simulations in the entire 
upper body of the patient. 
Results: In this work we developed a method of performing 
treatment verification of Eclipse breast plans with the Monte 
Carlo Fluka and show that dose differences up to 4% in the 
PTV and up to 70% in other healthy tissues (i.e., contra 
lateral breast) can be observed when the TPS plans are 
compared with Fluka simulations of the same plans. 
Conclusions: While the Varian TPS for conventional 
radiotherapy is widely used, the proton Eclipse TPS is only 
used in a few facilities, resulting in a dearth of comparison 
studies. In particular breast treatments with protons are in 
the early stages of investigation and not many groups so far 
have demonstrated the accuracy of TPSs with respect to this 
treatment site. With this study we demonstrate that 
treatment verification with Monte Carlo simulations is 
essential to better determine the dose deposited in the 
entire patient body, and in particular to the healthy tissues.  
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Purpose/Objective: To perform a dosimetric evaluation of 
arc-based modulated electron radiation therapy (arc-MERT) 
using a direct aperture optimization (DAO) algorithm.  
Materials and Methods: An arc-MERT plan was mimicked by 
setting a series of field ports with small angle increments 
(between 6° and 15° depending on the case). When possible, 
a single isocenter was used for the field set-up; this was not 
always possible due to the short source-to-skin distance 
(~70cm) used for MERT planning using the photon MLC for 
beam collimation. For each field port, beamlet dose 
distributions were generated for several different electron 
beam energies. A treatment plan is created by selecting and 
optimizing the shape and the weight of a certain number of 
initial apertures per beam energy and per field. Thus, 
different combinations of apertures can be investigated with 
the available field ports and beam energies. This approach 
was applied for two clinically motivated situations: a head 
and neck and a breast case. For the head and neck case, 13 
field ports spanning a 140° arc were set up using multiple 
isocenters. For the breast case, 6 field ports spanning a 30° 
arc were set up using a single isocenter. For both cases, 
many plans were generated using different combinations of 
apertures (between 10 and 90 apertures per plan). The dose 
homogeneity to the PTV as well as the doses to organs at risk 
(OAR) were determined and compared to photon plans. 
Results: Using arc-MERT, it is possible to achieve a high dose 
homogeneity to the PTV (V95%-V107% > 95%), which is similar 
to the photon plan. Good treatment plans can already be 
achieved using between 30 to 50 apertures and more than 
one electron beam energy. For the head and neck case, the 
organs at risk sparing was similar to the original VMAT plan, 
while the low dose bath could be substantially reduced with 
arc-MERT (V10% = 554 cc versus 1150 cc for VMAT). For the 
breast case, the high dose homogeneity to the PTV achieved 
with arc-MERT came at the cost of high ipsilateral lung doses 
(mean dose 20 Gy, V30Gy = 34%). If the CTV had to be 
adequately covered instead of the PTV (defined for 
tangential photon plans), the doses to the ipsilateral lung 
could be substantially reduced (mean dose 7.3 Gy, 
V30Gy=1%). 
Conclusions: arc-MERT offers the potential to achieve high 
dose homogeneity to the PTV similar to photon plans and 
depending on the case also similar OAR sparing while 
reducing the low dose bath. More work is required to define 
which sites would most benefit from arc-MERT. This work is 
supported by the Swiss Cancer Research grant KFS-3279-08-
2013. 
    
 
 
 
 
 
 
